Literature DB >> 33173211

Combined immune checkpoint inhibition for high-risk urothelial carcinoma.

Rebecca Tregunna1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33173211     DOI: 10.1038/s41585-020-00398-1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.

Authors:  Jianjun Gao; Neema Navai; Omar Alhalabi; Arlene Siefker-Radtke; Matthew T Campbell; Rebecca Slack Tidwell; Charles C Guo; Ashish M Kamat; Surena F Matin; John C Araujo; Amishi Y Shah; Pavlos Msaouel; Paul Corn; Jianbo Wang; John N Papadopoulos; Shalini S Yadav; Jorge M Blando; Fei Duan; Sreyashi Basu; Wenbin Liu; Yu Shen; Yuwei Zhang; Marc Daniel Macaluso; Ying Wang; Jianfeng Chen; Jianhua Zhang; Andrew Futreal; Colin Dinney; James P Allison; Sangeeta Goswami; Padmanee Sharma
Journal:  Nat Med       Date:  2020-10-12       Impact factor: 87.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.